Literature DB >> 12161411

In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci.

A C Fluit1, F-J Schmitz, J Verhoef, D Milatovic.   

Abstract

AZD2563 is a new oxazolidinone that has targeted activity against Gram-positive bacteria. The in vitro activity of AZD2563 and nine comparators against 1543 European enterococcal, staphylococcal and streptococcal isolates was determined. The compound is a potent oxazolidinone, with no isolate tested displaying an MIC > 4 mg/L and 94.4% having an MIC < or =2 mg/L. Compared with linezolid, the distribution of MICs for all species of bacteria tested, with the exception of Enterococcus faecium, was shifted by one or two dilution steps to lower values for AZD2563. Thus, this oxazolidinone is a promising new antibiotic for the treatment of infections with Gram-positive cocci.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161411     DOI: 10.1093/jac/dkf109

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  2 in total

1.  In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.

Authors:  Dongeun Yong; Jong Hwa Yum; Kyungwon Lee; Yunsop Chong; Sung Hak Choi; Jae Keol Rhee
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

2.  Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus.

Authors:  William J Peppard; Anne Daniels; Lynne Fehrenbacher; Jamie Winner
Journal:  Infect Drug Resist       Date:  2009-06-08       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.